Innate Pharma: FDA suspension lifted
This lifting of the suspension is based on the review of the fatal case, for which Innate, in collaboration with a steering committee of independent experts, concluded that there was no link between the death and lacutamab.
The lacutamab program is proceeding according to plan following the publication of the positive results in Sézary syndrome presented at the recent ASH 2023 annual meeting," comments Medical Director Sonia Quaratino.
Copyright (c) 2024 CercleFinance.com. All rights reserved.
Go to the original article.
Contact us to request a correction